China Cancer Drugs Market 2018-2024: Drugs, Cancer, Therapy, and Companies - Key Players are Merck, Celegene, Eli Lilly, Roche & Sino BioPharma

World News: . []

Dublin, Jan. 14, 2019 (GLOBE NEWSWIRE) -- The report has been added to offering. China Cancer Drugs Market is projected to reach US$ 30 Billion by the year 2024; owing to the increasing prevalence of various types of cancer, changing lifestyle & dietary habits, growing aging population, rising demand of targeted drug therapy and the patent expiration of key cancer drugs. Cancer is one of the leading causes of death worldwide and is a major public health burden in both developed and developing countries. The rate of cancer incidences in China is exploding very rapidly; nearly 4 million people diagnosed and almost 3 million died from it. For instance; due to increasing air pollution over the last couple of years, lung cancer has increased 50% in Beijing only. Anticancer drugs act like an inhibitor that prevents cancer cells to grow.In addition; factors like growing awareness regarding cancer diagnosis & treatment, advancement in cancer drugs and therapies, rise in cancer awareness programs like breast cancer screening, investment in healthcare infrastructure are expected to drive China anti-cancer drugs market positively over the forecast period. However, major side-effects of cancer drugs and its high cost are certainly restraining the China anti-cancer drugs market to reach its full potential.Based on the drugs type, China cancer drugs market is segmented into cytotoxic drugs, targeted drugs, Monoclonal Antibiotics, hormonal drugs, TCM and Others. The cytotoxic drugs segment is further classified into Antimetabolites, Plant Alkaloids and Alkylating Agents. On the basis of cancer type, China cancer drugs market is segmented into Lung, Stomach, Breast, Esophageal, Liver & Others. Lung, Breast and Stomach Cancer dominates the China anti-cancer drugs market and is expected to do so in the near future. By therapy type, the China anti-cancer drugs market is segmented into chemotherapy, targeted therapy, hormonal therapy and others. Chemotherapy and targeted therapy together held the major share of China cancer drugs market.Some of the prominent companies competing in the China Anti-Cancer Drugs Market, and profiled in the report include Merck, Celegene, Eli Lilly, Roche and Sino BioPharma.This market research report provides a complete analysis of the China Cancer Drugs Market, Growth Drivers, Challenges, and their projections for the upcoming years.Growth Drivers


For more information about this report visit

Research and Markets also offers services providing focused, comprehensive and tailored research.

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Oncology Drugs

More news and information about Research and Markets

Published By:

Globe Newswire: 15:20 GMT Monday 14th January 2019

Published: .

Search for other references to "china" on SPi News


Previous StoryNext Story

SPi News is published by Sector Publishing Intelligence Ltd.
© Sector Publishing Intelligence Ltd 2019. [Admin Only]
Sector Publishing Intelligence Ltd.
Agriculture House, Acland Road, DORCHESTER, Dorset DT1 1EF United Kingdom
Registered in England and Wales number 0751938.
Privacy Policy | Terms and Conditions | Contact Us